Kornimate/medical-research-clean huggingface dataset:
impact of remote ischemic postconditioning on autonomic function in stroke patients

Conditions: Ischemic Stroke

Summary: the purpose of this study is to determine whether remote ischemic postconditioning (ripostc) initiates autonomic nervous system response and affects the prognosis in patients with acute ischemic stroke.

remote ischemic postconditioning (ripostc) has proven effective in reducing the ischemia-reperfusion injury. but the defensive mechanism of ripostc still unclear. stroke is frequently associated with autonomic dysfunction. heart rate variability (hrv) represents the autonomic nervous system activity.this study aims to investigate whether ripostc correlates with autonomic function and thus predicts prognosis of stroke.

Eligibility criteria:
inclusion criteria: 1. diagnosed as ischemic stroke according to the chinese guideline of diagnosis and treatment of acute ischemic stroke 2010 2. age between 18 to 85 years old 3. initial ischemic stroke within 14 days or less. 4. national institutes of health stroke scale (nihss)score 0-15 5. modified rankin scale(mrs)score 1-4 6. informed consent exclusion criteria: 1. intravenous or arterial thrombolysis, or revascularization 2. acute myocardial infarction,atrial fibrillation,arrhythmia,or cardiogenic cerebral embolism 3. systolic blood pressure(sbp)\>200mmhg after medication treatment 4. plasma fibrinogen\>7g/l 5. upper limb fracture or percutaneous injury 6. subclavian artery stenosis 7. with severe cardiac,respiratory,hepatic,and renal dysfunction or malignant tumor 8. simultaneous participation in another interventional study 9. pregnancy

Keywords: remote ischemic postconditioning autonomic function heart rate variability acute ischemic stroke prognosis
evaluation of preoperative risk factors in children

Conditions: Anesthesia Morbidity; Preterm Birth; Difficult or Failed Intubation

Summary: 1. the investigators aimed to make a more advanced risk assessment in predicting preoperative intensive care unit admission in pediatric patients. 2. the investigators aimed to better define the pediatric patient population and identify preoperative risk factors in detail in order to reduce perioperative complications.

the aim of this study was to evaluate preoperative risk factors and determine their efficacy in predicting icu admission after emergency or elective surgery in pediatric patients of all age groups. to achieve this aim, data such as gender, age, height, weight, history of prematurity, post-conceptional week, asa ps score, accompanying systemic diseases, history of previous anesthesia, history of emergency or elective surgery, tumor surgery, chemotherapy and radiotherapy, surgical risk classification, difficult airway will be collected.

Eligibility criteria:
inclusion criteria: * children under the age of 18 who will have an operation in the pediatric surgery operating room. exclusion criteria: * children who are scheduled for surgery in pediatric surgery room but are hospitalized in the intensive care unit.(children admitted directly from the intensive care units to the operating rooms)

Keywords: asa-ps surgical risk risk assessment preoperative prediction of icu admission
combined antibody screening for celiac and diabetes evaluation

Conditions: Type 1 Diabetes; Celiac Disease

Summary: the cascade study (combined antibody screening for celiac and diabetes evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (t1d) and celiac disease (cd) is feasible to prevent diabetic ketoacidosis (dka), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. it has two arms, a birth cohort and a kids (cross sectional) cohort.


Eligibility criteria:
inclusion criteria: * child must be between 0 to 8 months in age or between 4 to 7 years in age. child must be born in the state of washington. exclusion criteria: -

Keywords: type 1 diabetes celiac disease diabetes celiac gluten autoantibodies
effect of the consumption of a fermented milk on common infections in shift-workers

Conditions: Infectious Diseases; Healthy Subjects; Respiratory Tract Infections; Sore Throat; Sinusitis; Otitis; Bronchitis; Pneumonia; Influenza; Gastroenteritis

Summary: this single-center, randomized, double-blind and controlled study aims to examine the effect of a fermented dairy product containing the probiotic lactobacillus casei dn-114 001 (actimel® = tested product) on the incidence of respiratory and gastro-intestinal common infectious diseases (cumulated number of infections during the intervention period: primary criteria), and on immune functions in healthy shift workers. volunteers received either 200g/day of tested product (n=500) or control product (n=500) for 3-months, followed by a 1-month follow-up.


Eligibility criteria:
inclusion criteria: male and female aged 18-65 years; working in 2- or 3-shift work patterns (including night work); same job position for at least 4.5 months; a 19 to 30 kg/m2 body mass index; no symptoms of cids during the 2 weeks before product consumption; agreeing to a written informed consent. exclusion criteria: part time work (\<90%); allergy/hypersensitivity to components of the study product; severe respiratory allergy; a situation which, in the investigator's opinion, could interfere with optimal participation or constitute a special risk for the volunteer; a history of chronic metabolic/gastro-intestinal disease (except appendectomy); surgery/intervention requiring general anesthesia in the last 4 weeks; administration of systemic/topical treatments likely to interfere with the evaluation parameters in the last 4 weeks; chronic disease requiring antibiotics/antiseptics/anti-inflammatory medications; special medicated diet; chronic/iatrogenic immunodeficiency; cardiac/renal/respiratory insufficiency; severe evolutive/chronic pathology; pregnancy, breast feeding or lacking effective contraception in females; susceptibility not to comply with dietary recommendation during the study period.

Keywords: probiotic - lactobacillus casei dn114-001 dairy product - infections - shiftworkers common infectious diseases, occuring in healthy subjects, including upper respiratory tract infections (defined as rhinopharyngitis, sore throat, sinusitis and otitis), lower respiratory tract infections (defined as bronchitis, pneumopathy and flu and flu-like syndromes), and gastrointestinal tract infection defined as gastroenteritis.
a study of adalimumab in japanese subjects with moderately to severely active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to assess the efficacy and safety of adalimumab in japanese subjects with moderately to severely active ulcerative colitis (uc).

patients who meet all of the inclusion criteria and none of the exclusion criteria are randomized 1:1:1 to receive subcutaneous injections of adalimumab at either 160/80 mg at week 0/2 and 40 mg every other week (eow) starting at week 4 to week 50, 80/40 mg at week 0/2 and 40 mg eow starting at week 4 to week 50, or placebo eow starting at week 0 to week 50 under the double-blind condition. at or after week 8, participants who have inadequate response during the double-blind period can switch to the rescue arm, where participants from the placebo group initially receive adalimumab 160 mg and 80 mg 2 weeks later and those from the adalimumab group receive adalimumab 40 mg initially and 2 weeks later under double-blind conditions. all participants in the rescue arm then receive 40 mg adalimumab eow until week 50. participants who complete the 52-week double-blind period receive open-label adalimumab 40 mg eow starting at week 52 and continuing until the end of the study. participants who have an inadequate response or disease flare can dose escalate to 80 mg eow at or after week 60. participants who dose escalate to 80 mg eow and continue to have an inadequate response or disease flare are withdrawn from the study.

Eligibility criteria:
inclusion criteria: * diagnosis of ulcerative colitis for greater than 90 days prior to baseline. * active ulcerative colitis with a mayo score of 6-12 points at baseline and endoscopy subscore of 2-3 during the screening period, despite concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below): * stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to baseline. and/or * at least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-mp) prior to baseline, with a dose of azathioprine ≥ 50 mg/day or 6-mp ≥ 30 mg/day, or a dose that was the highest tolerated by the patient. exclusion criteria: * history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery. * patients with disease limited to the rectum. * indeterminate colitis and/or crohn's disease. * received any biological therapy (including infliximab) in the past. * history of tuberculosis or malignancy. * pregnant women. * patients with positive c. difficile stool assay at screening. * current diagnosis of fulminant colitis and/or toxic megacolon.

Keywords: ulcerative colitis
isokinetic parameters and the amputee mobility predictor scale

Conditions: Amputation, Traumatic

Summary: there is very limited research examining isokinetic parameters and activity level in patients with amputation.. therefore, the aims of this study were to illustrate isokinetic measurements including strength and proprioception and to analyze the correlation between those isokinetic parameters and activity level and to predict amputee mobility score. it is hypothesized that muscle strength and proprioception were associated with activity level and could be used to estimate amputee mobility scale score in patients with amputation.

isokinetic measurements are used in the rehabilitation of amputee patients and to evaluate the effectiveness of rehabilitation. the parameters that are frequently looked at in these measurements are isokinetic muscle strength and proprioception. there is very limited research examining isokinetic parameters and activity level in patients with amputation.. therefore, the aims of this study were to illustrate isokinetic measurements including strength and proprioception and to analyze the correlation between those isokinetic parameters and activity level and to predict amputee mobility score. we hypothesized that muscle strength and proprioception were associated with activity level and could be used to estimate amputee mobility scale score in patients with amputation

Eligibility criteria:
inclusion criteria: * aged 18-65 years * time after amputation ≥ 6 months * unilateral or bilateral amputation above the ankle level exclusion criteria: * upper extremity amputation * the presence of musculoskeletal or neurological disease that could cause functional impairment other than amputation * the presence of neurological deficit
addressing fear and risk of vasovagal reactions among high school donors

Conditions: Blood Donors

Summary: in this study, high school donors will be asked about their blood donation-related fears prior to their donation. half of the donors reporting fear will be assigned to a brief coping skills intervention.

in this study the investigators will ask high school donors about their blood donation-related fears prior to their donation. among those who report donation fear, half will be randomly assigned to receive a brief presentation of coping strategies administered via a computer tablet. the investigators will compare reaction rates and return behavior for the donors and high school drives where the study was conducted to the reaction and retention rates from similar blood drives where no data was collected. the investigators will also examine whether asking about the specific types of fear improves the prediction of syncopal or presyncopal reactions beyond the predictive value of a single fear question. finally, the investigators will examine whether providing coping information to help manage the fear improves syncopal reaction rates and/or donor retention rates among fearful donors.

Eligibility criteria:
inclusion criteria: * to be eligible for inclusion in this study, the individual must have presented to donate blood at a new york blood center high school blood drive where data is being collected and have passed the health screening process. exclusion criteria: * less than 16 years of age; inability to read and comprehend english

Keywords: blood donor, fear, vasovagal reaction
effect of lactobacillus casei dg (enterolactis plus®) in patient with irritable bowel syndrome: a pilot study

Conditions: Irritable Bowel Syndrome

Summary: the aim of the study is to collect data for the assessment of the lactobacillus casei dg (enterolactis plus®) effect on overall abdominal pain/discomfort, symptoms and gut microbiota composition in patients with irritable bowel syndrome.

the aim of the study is to collect data for the assessment of the lactobacillus casei dg (enterolactis plus®) effect on overall abdominal pain/discomfort, symptoms and gut microbiota composition in patients with irritable bowel syndrome. the investigators suppose that, due to the immunomodulatory action of probiotics, overall abdominal pain/discomfort and symptoms will improve, fecal immunoglobulin a levels will change, pro-inflammatory cytokine levels will decrease and the production of regulatory cytokines as interleukin 10 will improve following consumption of lactobacillus casei dg (enterolactis plus®).

Eligibility criteria:
inclusion criteria: * age \> 18 years and ≤ 65 years. * a positive diagnosis of irritable bowel syndrome regardless of bowel habit (both males and females), according to rome iii criteria. * negative outcome of barium enema or left colonoscopy within the previous two years. * negative relevant additional screening or consultation whenever appropriate. * ability of conforming to the study protocol. exclusion criteria: * presence of any relevant organic, systemic or metabolic disease (particularly significant history of cardiac, renal, neurological, psychiatric, oncology, endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will be deemed clinically significant on the basis of predefined values. * ascertained intestinal organic diseases, including ascertained celiac disease or inflammatory bowel diseases (crohn's disease, ulcerative colitis, diverticular disease, infectious colitis, ischemic colitis, microscopic colitis). * previous major abdominal surgeries. * active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment are also acceptable). * untreated food intolerance such as ascertained or suspected lactose intolerance, as defined by anamnestic evaluation or, if appropriate, lactose breath test. * assumption of probiotics or topic and/or systemic antibiotic therapy during the last month. * systematical/frequent assumption of contact laxatives. * females of childbearing potential, in the absence of effective contraceptive methods. * pregnant women. * inability to conform with protocol. * treatment with any investigational drug within the previous 30 days. * recent history or suspicion of alcohol abuse or drug addiction. * previous participation in this study.

Keywords: irritable bowel syndrome lactobacillus casei dg microbiota
diet intervention, head and neck cancer, feasibility

Conditions: Head and Neck Cancer

Summary: this study will examine the effects of a dietary intervention in post-treatment head and neck cancer survivors on the ability to function physically, tiredness, and quality of life, as well as on changing markers in the blood that are associated with better recurrence and survival.


Eligibility criteria:
inclusion criteria: patients will be eligible to participate if they are 1) diagnosed with stage i - iv oral, hypopharyngeal, nasopharyngeal, oropharyngeal, or laryngeal cancer; 2) age 19+; 3) at least 6 months - 2 years post-treatment; 4) able to consume foods orally; 5) no evidence of disease; 6) english-speaking exclusion criteria: patients will not be eligible to participate if they have 1) dementia or organic brain syndrome; 2) severe emotional distress; 3) active schizophrenia; 3) another diagnosis of cancer in the past five years (not including skin or cervical cancer in situ)

Keywords: diet nutrition survival recurrence cruciferous dark leafy greens
etonogestrel implants protect ovarian reserve function in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: this clinical trial aims to test in female patients with systemic lupus erythematosus (sle). the main question it seeks to answer is whether etonogestrel implants can protect ovarian reserve function in patients with sle. participants will be randomly divided into a test group and a control group. the test group will be implanted subcutaneously with etongestrel for one year. researchers won't intervene in the control group. after three months of drug-eluting, researchers will compare measures of ovarian reserve function in the test and control groups to see if etonogestrel implants can protect ovarian reserve function in patients with sle.


Eligibility criteria:
inclusion criteria: 1. systemic lupus erythematosus was confirmed 2. 18-37 years old exclusion criteria: 1. history of sex chromosome abnormalities 2. history of abnormal thyroid function 3. history of abnormal adrenal function 4. history of pituitary disease 5. history of sexual hormone drug use in the past 3 months 6. history of ovarian tumors or invasive ovarian operations 7. pregnancy 8. have a birth plan in the next 1 year 9. ovarian failure
study of the intravitreal plasma kallikrein inhibitor, kvd001, in subjects with center-involving diabetic macular edema (cidme)

Conditions: Diabetic Macular Edema

Summary: this is a clinical study where patients with diabetes and a vision threatening eye condition called "diabetic macular edema" receive four injections into the eye at monthly intervals. the patients will already have tried the standard of care without complete success. the patients will be randomized to receive either a high dose, a low dose or a sham control treatment. the study will evaluate whether the new treatment improves vision and whether it changes the underlying course of the disease in the eye.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of type i or type ii diabetes mellitus (dm). * bcva of ≥19 letters (\~20/400) and ≤73 letters (\~20/40) in the study eye and ≥34 letters(\~20/200 or better) in the fellow eye. * presence of cidme in the study eye defined as cst ≥305 μm in women and ≥320 μm in men * subjects first anti-vegf injection in the study eye occurred ≤36 months. * subjects have received at least 3 anti-vascular endothelial growth factor (vegf) injections in the study eye within a 6-month period. * the last anti-vegf injection in the study eye is ≥ 8 weeks. exclusion criteria: * evidence of ocular pathology (e.g. visually significant cataract) that impacts subject's vision in the study eye from any cause other than dme. * evidence/presence of amblyopia, vitreomacular traction, epiretinal membrane, foveal atrophy, or foveal ischemia, or any other condition in the macula that is thought to impair the subject's vision (other than dme). * prior treatment with panretinal photocoagulation or focal grid macular photocoagulation in the study eye within the previous 3 months. * prior treatment with intravitreal (ivt) steroid in the study eye (in the previous 3 months for triamcinolone, previous 6 months for ozurdex and at any time for iluvien). * prior treatment with topical nsaids or topical steroids in the study eye within 1 month. * prior treatment with systemic corticosteroids or systemic anti-vegf therapy within 3 months. * prior vitrectomy in the study eye. * prior intraocular surgery in the study eye except for cataract surgery. cataract surgery within the previous 6 months in the study eye is excluded. * intraocular pressure (iop) of \>22 mmhg in the study eye or use of \>2 antiglaucoma agents (combination agents count as 2 agents) in the study eye. * evidence of infectious dacrocystitis, significant blepharitis, active conjunctivitis, infectious keratitis, or scleritis in either eye, or any other condition that might affect the safety of the ivt injection. * current active proliferative diabetic retinopathy (pdr), active anterior segment neovascularization (asnv), active retinal neovascularization, or the presence of vitreous hemorrhage in the study eye. * poorly controlled dm. * uncontrolled hypertension * prior treatment with ocriplasminin the study eye within 3 months
association between malnutrition and clinical outcomes in the intensive care unit

Conditions: Critical Illness; Malnutrition

Summary: previous studies have demonstrated the direct associations between malnutrition and hospital mortality as well as the length of stay in critically ill patients. however, the validity of these results may be limited by inappropriate diagnoses of malnutrition, small sample size, possible treatment bias, and sub-optimal statistical adjustment. this study aimed to further examine the aforementioned associations by addressing these limitations.

design: * prospective cohort study setting: * 35-bedded integrated intensive care/ high dependency unit in ng teng fong general hospital. patients' status can be changed between icu-status and hd-status within the same icu-/ hd-bed participants: * all adult patients who will be admitted to the unit between august-2015 to october-2016 for ≥ 24 hours intervention: nil. given the observational nature of this study, no attempt will be made to standardize care, including nutritional practices. measurement: * as per routine care, a validated nutritional assessment tool \[7-point subjective global assessment (7-point sga)\] will be used to determine patients' nutritional status within 48 hours of icu admission * the primary outcomes will be hospital mortality and icu length of stay. to measure hospital mortality, all patients will be followed until hospital discharge or death for up to one year after icu admission. for icu length of stay (in days), duration will be measured from the date of the first icu admission to the date of the first change in icu-status to hd-status or discharge to the general ward analysis: * modified cox regression model with robust variance and logistic regression will be used to determine the associations between nutritional status and hospital mortality. analyses will be conducted in two ways: 1) presence versus absence of malnutrition, and 2) dose-dependent association for each 1-point decrease in the 7-point sga * multiple linear regression will be applied to determine the associations between nutritional status and icu length of stay

Eligibility criteria:
inclusion criteria: * ≥ 18 years old who had ≥ 24 hours length of stay in the icu * received a nutrition assessment (7-point sga) from a dietitian within 48 hours of admission to the icu exclusion criteria: * nil

Keywords: subjective global assessment nutritional status hospital mortality length of stay malnutrition